PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 81
Special Issue Editors
Interests: PET/CT; theragnostics; prostate cancer; lymphoma; thyroid cancer
Interests: PET; nuclear medicine; hybrid imaging; meta-analysis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the swiftly advancing domain of functional imaging, novel radiopharmaceuticals are emerging as new headliners in the rapidly evolving fields of oncologic and inflammatory diseases, trying to bring the promise of a patient-tailored medicine to reality.
In this setting, new-generation radiopharmaceuticals are assuming great relevance both in studying different features of the disease, such as the tumour stroma in place of cancer cells’ metabolism through radiolabelled fibroblast activation protein inhibitors, and in treatment planning, individuating and quantifying the expression of specific therapeutic targets (e.g., PD-L1) in order to modulate treatments and predict their success.
We are pleased to invite you to contribute to this Special Issue, PET/CT for Diagnosis, Treatment Planning and Prognosis Prediction in Oncology and Inflammatory Diseases, which aims to collect the most interesting papers on the applications of novel radiopharmaceuticals in oncologic and inflammatory diseases.
In this Special Issue, original research articles and reviews are welcome. Pre-clinical or clinical studies, experimental or observational studies, and senior or young investigators will be considered for publication.
Dr. Alessio Rizzo
Prof. Dr. Giorgio Treglia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nuclear medicine
- PET/CT
- radiopharmaceuticals
- theragnostics
- oncology
- inflammation
- personalised medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
